BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai C, Sung F, Hsieh L, Tang R, Chiou H, Wu F, Yeh C. Associations Between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and Survival of Colorectal Cancer (CRC) Patients Treated with 5-Fluorouracil-Based Chemotherapy. Ann Surg Oncol 2013;20:599-606. [DOI: 10.1245/s10434-013-3069-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Yeh C, Lai C, Chang S, Hsieh L, Tang R, Sung F, Lin Y. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. Int J Clin Oncol 2017;22:484-93. [DOI: 10.1007/s10147-016-1080-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Sobral-Leite M, Lips EH, Vieira-Monteiro HA, Giacomin LC, Freitas-Alves DR, Cornelissen S, Mulder L, Wesseling J, Schmidt MK, Vianna-Jorge R. Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients. PLoS One 2017;12:e0189750. [PMID: 29267323 DOI: 10.1371/journal.pone.0189750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
3 De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates 2015;20:39-70. [DOI: 10.1016/j.drup.2015.05.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
4 Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-khoueiry R, Falcone A, Lenz H. Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics J 2014;14:322-7. [DOI: 10.1038/tpj.2014.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
5 Bonin S, Donada M, Bussolati G, Nardon E, Annaratone L, Pichler M, Chiaravalli AM, Capella C, Hoefler G, Stanta G. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. Tumour Biol 2016;37:7295-303. [PMID: 26666825 DOI: 10.1007/s13277-015-4543-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
6 Wang Y, Zha L, Liao D, Li X. A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer. Int J Genomics 2014;2014:312102. [PMID: 25401099 DOI: 10.1155/2014/312102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]